News

Findings from Scripps Research reveal promising drug targets with potential to block coronaviruses at multiple stages of infection—even across different strains.

Study led by Scripps Research, Texas A&M and additional institutions highlights that the world’s deadliest infectious disease needs novel, effective antibiotics.

A new platform developed at Scripps Research enables fast, scalable protein evolution—opening the door to new therapies and diagnostics, and to predicting resistance mutations across many disease areas.

Phase 3 trial results from Scripps Research and collaborators helped support FDA approval of ENCELTO, the first cell-based therapy for a neurodegenerative retinal condition called MacTel.

Scripps Research scientists reveal how wearable sensors and artificial intelligence could transform the way we detect and manage pre-diabetes.

The grant from the National Center for Advancing Translational Sciences (NCATS) supports the ongoing development of the Biomedical Data Translator—an open-source resource to accelerate human health insights.

Origin-of-life scientists from Scripps Research reveal how the sugar ribose may have been selected as one of life’s building blocks.

First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous.Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions.

By analyzing just a drop of blood, this microchip gives researchers quicker-than-ever insight into how a person’s antibodies are interacting with a virus or other pathogen.

Scripps Research scientists’ new approach combines two immune-activating molecules known as adjuvants.

CLBR001 + ABBV-461 is a novel, investigational, two-part, switchable chimeric antigen T cell (sCAR-T) immunotherapy designed to treat solid tumors.

Cell-based therapy with roots at Scripps Research offers new hope for patients with macular telangiectasia type 2.

Scripps Research’s insights into sex-based differences in brain chemistry could guide personalized treatment strategies for alcohol use disorder.

More than 70% of the drugs identified by artificial intelligence extended the lifespan of C. elegans worms.

Certain antibodies blocked nearly 70% of HIV strains, including those typically hard to target.

Chi-Huey Wong Laboratories for Biomedical Research recognized for sustainable construction.

The ceremony represented the largest graduating class since the doctoral program’s inception in 1989.

President and CEO Pete Schultz is honored for expanding the genetic code and the development and application of large scale “diversity-based” approaches to the discovery of novel proteins, drugs and modern materials.

Researchers show that mpox circulated among humans in Nigeria for eight years before the international outbreak, highlighting the need for improved surveillance.

North American and African clinical trials led by Scripps Research, IAVI and additional collaborators across the U.S. and Africa mark progress toward an effective HIV vaccine.

Breakthrough from Scripps Research, the San Diego Zoo Wildlife Alliance, Max Planck Institute and other collaborators paves way for stem cell-based reproduction.

Latest book by Scripps Research executive vice president guides readers through medical breakthroughs that are primed to extend healthspan

Scripps Research scientists used computer modeling to illustrate how antibodies use fatty molecules known as lipids to recognize the HIV virus.

Scripps Research and Georgia Institute of Technology scientists’ discovery could help understand how life evolved on Earth and lead to better biofuel production.